Layer displays the percentage of claims for prescription drugs among Medicare Part D beneficiaries that were for opioid drugs in 2015. Data is available by county, ZIP Code Tabulation Area (ZCTA) and by physician (address).
This layer displays opioid overdose mortality rates from the CDC’s National Vital Statistics System – Mortality database. Data are 5-year aggregates for 2013-17 and grouped by ICD-10 codes.
This map layer displays the number of prescription opioid pain pills (total and per capita) purchased for sale in counties across the United States. Data are based on CARES of analysis data made available by the Washington Post.
This layer displays the average annual number of high-strength (>30 MME) prescription opioid pain pills purchased for sale in counties across the United States. Data are based on CARES of analysis data made available by the Washington Post.
This layer displays the percentage of Medicare Beneficiaries with a drug or substance use disorder. The prevalence among Medicare beneficiaries is based on Medicare insurance claims (for specific inpatient diagnosis or procedure codes) in 2017.
Layer displays the percentage of claims for prescription drugs among Medicare Part D beneficiaries that were for opioid drugs in 2017. Data is available by county, ZIP Code Tabulation Area (ZCTA) and by physician (address).
This layer displays opioid overdose mortality rates from the CDC’s National Vital Statistics System – Multiple Cause of Death database. Data are 5-year aggregates for 2014-18 and grouped by ICD-10 codes.
This layer displays opioid overdose mortality rates from the CDC’s National Vital Statistics System – Multiple Cause of Death database. Data are 5-year aggregates for 2015-19 and grouped by ICD-10 codes.
Layer displays the percentage of claims for prescription drugs among Medicare Part D beneficiaries that were for opioid drugs in 2018. Data is available by county, ZIP Code Tabulation Area (ZCTA) and by physician (address).
This layer displays the percentage of Medicare Beneficiaries with a drug or substance use disorder. The prevalence among Medicare beneficiaries is based on Medicare insurance claims (for specific inpatient diagnosis or procedure codes) in 2018.